According to the study, patients treated with this drug were 79% less likely to develop severe forms of the disease than those who received a placebo. This is
According to the study, patients treated with this drug were 79% less likely to develop severe forms of the disease than those who received a placebo.
This is a study that could revolutionize the way the Covid-19 virus is treated. A drug called SNG001 would reduce by 79% the risk of developing a severe form of the disease Covid-19, according to preliminary results published on Monday by the British laboratory Synairgen, which produces the product. This inhaled treatment uses beta-interferon, a natural protein that mediates the body’s response to the virus.
A study conducted by the University of Southampton of 101 patients concluded that patients treated with this drug were 79% less likely than those receiving a placebo to develop severe forms of the disease, requiring a ventilator or life. – threatening. Patients treated with SNG001 were more than twice as likely to recover compared to those who received placebo.
READ ALSO >> Dexamethasone against Covid: “Attention to fugitive media and politics”
summer offer: Take advantage of a special offer for 2 months for €1 I subscribe
Three patients (6%) treated with placebo died, while there were no deaths among those treated with SNG001.
Protect your lungs
The study was carried out on a relatively small sample of patients and was not subject to peer review, but according to Synairgen CEO Richard Marsden, it could be “a big step forward”.
READ ALSO >> Consequences of respiratory Covid-19: lungs under strict surveillance
“The results confirm our belief that interferon-beta (…) has enormous potential as an inhaled therapy to restore the immune response of the lungs, improving protection, accelerating recovery and counteracting the impact of the SARS-CoV-2 virus,” he said in a press release. Pr Tom Wilkinson, professor of respiratory medicine at the University of Southampton, who led the trial.
READ ALSO >> Serious forms of Covid-19: runway for identifying the most vulnerable people
Professor Stephen Holgate, co-founder of Synairgen, emphasized that the treatment “restores the lung’s ability to neutralize the virus or any mutation of the virus or co-infection with another respiratory virus such as influenza or RSV (respiratory virus common, EDITOR’S NOTE) as this could happen in winter in the event of a re-emergence of COVID-19”.
Read our full file
“COVID-19”, the new coronavirus
Covid-19 : two vaccine projects generate immune response” Covid-19 : the first French study to understand persistent symptoms Fear of a second wave of Covid-19… how about our European neighbors?
Until then, only the drug, dexamethasone, proved that it could save patients from Covid-19. Another treatment, the antiviral remdesivir, makes it possible to reduce the length of hospital stay, but not mortality.
Date of update: July 20, 2020, 10:58 am
Categories: Optical Illusion
Source: newstars.edu.vn